The Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) is where the next generation of cures will be made.
-
Our Experts
View our experts by disease program.
-
Research
Our experts are uniquely positioned to make progress against cancer.
Turning Research into Results
Neoadjuvant Therapy
Neoadjuvant immunotherapy, usually with a single or combination of immune checkpoint inhibitors, is given before surgery to decrease the size of tumors to make surgical removal easier and to prevent cancer recurrence. Bloomberg~Kimmel Institute for Cancer Immunotherapy research provided the first published report of neoadjuvant immunotherapy, using PD-1 immune checkpoint inhibitors. In some cases, cancers, including non-small cell lung cancers, melanoma skin cancers, Merkel Cell Carcinoma, head and neck cancers, had completely disappeared by the time of surgery.
Vaccine
50 Years of Immunology Research
Cancer care transitions to outpatient settings, with the Kimmel Cancer Center at Johns Hopkins expanding to occupy its largest footprint. Immunotherapy breakthroughs harness the immune system's natural killing power against cancer, marking significant clinical progress. The adoption of Multidisciplinary Clinics, where specialists collaborate across various fields of cancer care, becomes standard practice, leading to enhanced therapeutic approaches and improved patient survival rates.
Research News: AstroPath
Janis Taube, MD, MsC, explains how AstroPath, a platform that she developed with Alex Szalay, PhD, of Johns Hopkins University pairs astronomy with pathology to identify predictive biomarkers for cancer immunotherapy.
More About Our Research
What to Expect Treatment at BKI
While there are FDA-approved immune therapies, the science is still new. Most patients who receive immune-based cancer treatments do so as part of a clinical trial. Our investigator-initiated trials are not sponsored by drug companies, but are fully designed, executed, analyzed and published under the direction of our clinician-scientists.
Nurse navigator helps patients choose and register for clinical trials, and helps guide their care.
Biopsy service helps patients manage their test needs before and during treatment.
Patients continue receiving multi-disciplinary care from their immunotherapy team and oncologist.
